title: Fingolimod and multiple sclerosis: four cautionary tales.
authors.forename: Dennis
authors.initials: D
authors.lastname: Bourdette
authors.forename: Don
authors.initials: D
authors.lastname: Gilden
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001921:Brain / Q000473:pathology*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D020804:Encephalitis, Varicella Zoster / Q000188:drug therapy*; D005260:Female; D000068876:Fingolimod Hydrochloride; D006562:Herpes Zoster / Q000150:complications*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000188:drug therapy*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology*; D000069442:Natalizumab; D009413:Nerve Fibers, Myelinated / Q000473:pathology*; D011409:Propylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine